432 related articles for article (PubMed ID: 18722008)
1. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial.
Kerem E; Hirawat S; Armoni S; Yaakov Y; Shoseyov D; Cohen M; Nissim-Rafinia M; Blau H; Rivlin J; Aviram M; Elfring GL; Northcutt VJ; Miller LL; Kerem B; Wilschanski M
Lancet; 2008 Aug; 372(9640):719-27. PubMed ID: 18722008
[TBL] [Abstract][Full Text] [Related]
2. Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis.
Sermet-Gaudelus I; Boeck KD; Casimir GJ; Vermeulen F; Leal T; Mogenet A; Roussel D; Fritsch J; Hanssens L; Hirawat S; Miller NL; Constantine S; Reha A; Ajayi T; Elfring GL; Miller LL
Am J Respir Crit Care Med; 2010 Nov; 182(10):1262-72. PubMed ID: 20622033
[TBL] [Abstract][Full Text] [Related]
3. Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis.
Wilschanski M; Miller LL; Shoseyov D; Blau H; Rivlin J; Aviram M; Cohen M; Armoni S; Yaakov Y; Pugatsch T; Cohen-Cymberknoh M; Miller NL; Reha A; Northcutt VJ; Hirawat S; Donnelly K; Elfring GL; Ajayi T; Kerem E
Eur Respir J; 2011 Jul; 38(1):59-69. PubMed ID: 21233271
[TBL] [Abstract][Full Text] [Related]
4. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations.
Wilschanski M; Yahav Y; Yaacov Y; Blau H; Bentur L; Rivlin J; Aviram M; Bdolah-Abram T; Bebok Z; Shushi L; Kerem B; Kerem E
N Engl J Med; 2003 Oct; 349(15):1433-41. PubMed ID: 14534336
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of premature stop codon readthrough in the CFTR gene by Ataluren (PTC124) derivatives.
Pibiri I; Lentini L; Melfi R; Gallucci G; Pace A; Spinello A; Barone G; Di Leonardo A
Eur J Med Chem; 2015 Aug; 101():236-44. PubMed ID: 26142488
[TBL] [Abstract][Full Text] [Related]
6. Limited premature termination codon suppression by read-through agents in cystic fibrosis intestinal organoids.
Zomer-van Ommen DD; Vijftigschild LA; Kruisselbrink E; Vonk AM; Dekkers JF; Janssens HM; de Winter-de Groot KM; van der Ent CK; Beekman JM
J Cyst Fibros; 2016 Mar; 15(2):158-62. PubMed ID: 26255232
[TBL] [Abstract][Full Text] [Related]
7. PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model.
Du M; Liu X; Welch EM; Hirawat S; Peltz SW; Bedwell DM
Proc Natl Acad Sci U S A; 2008 Feb; 105(6):2064-9. PubMed ID: 18272502
[TBL] [Abstract][Full Text] [Related]
8. Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis.
Clancy JP; Bebök Z; Ruiz F; King C; Jones J; Walker L; Greer H; Hong J; Wing L; Macaluso M; Lyrene R; Sorscher EJ; Bedwell DM
Am J Respir Crit Care Med; 2001 Jun; 163(7):1683-92. PubMed ID: 11401894
[TBL] [Abstract][Full Text] [Related]
9. In vitro prediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot study.
Sermet-Gaudelus I; Renouil M; Fajac A; Bidou L; Parbaille B; Pierrot S; Davy N; Bismuth E; Reinert P; Lenoir G; Lesure JF; Rousset JP; Edelman A
BMC Med; 2007 Mar; 5():5. PubMed ID: 17394637
[TBL] [Abstract][Full Text] [Related]
10. A pilot study of the effect of gentamicin on nasal potential difference measurements in cystic fibrosis patients carrying stop mutations.
Wilschanski M; Famini C; Blau H; Rivlin J; Augarten A; Avital A; Kerem B; Kerem E
Am J Respir Crit Care Med; 2000 Mar; 161(3 Pt 1):860-5. PubMed ID: 10712334
[TBL] [Abstract][Full Text] [Related]
11. Ignoring the nonsense: a phase II trial in cystic fibrosis.
Hyde SC; Gill DR
Lancet; 2008 Aug; 372(9640):691-2. PubMed ID: 18722009
[No Abstract] [Full Text] [Related]
12. Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial.
Kerem E; Konstan MW; De Boeck K; Accurso FJ; Sermet-Gaudelus I; Wilschanski M; Elborn JS; Melotti P; Bronsveld I; Fajac I; Malfroot A; Rosenbluth DB; Walker PA; McColley SA; Knoop C; Quattrucci S; Rietschel E; Zeitlin PL; Barth J; Elfring GL; Welch EM; Branstrom A; Spiegel RJ; Peltz SW; Ajayi T; Rowe SM;
Lancet Respir Med; 2014 Jul; 2(7):539-47. PubMed ID: 24836205
[TBL] [Abstract][Full Text] [Related]
13. No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutations.
Clancy JP; Rowe SM; Bebok Z; Aitken ML; Gibson R; Zeitlin P; Berclaz P; Moss R; Knowles MR; Oster RA; Mayer-Hamblett N; Ramsey B
Am J Respir Cell Mol Biol; 2007 Jul; 37(1):57-66. PubMed ID: 17347447
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological induction of CFTR function in patients with cystic fibrosis: mutation-specific therapy.
Kerem E
Pediatr Pulmonol; 2005 Sep; 40(3):183-96. PubMed ID: 15880796
[TBL] [Abstract][Full Text] [Related]
15. Pharmacologic therapy for stop mutations: how much CFTR activity is enough?
Kerem E
Curr Opin Pulm Med; 2004 Nov; 10(6):547-52. PubMed ID: 15510065
[TBL] [Abstract][Full Text] [Related]
16. PTC124 for cystic fibrosis.
Goodier JL; Mayer J
Lancet; 2009 Apr; 373(9673):1426; author reply 1426-7. PubMed ID: 19394530
[No Abstract] [Full Text] [Related]
17. Toward a rationale for the PTC124 (Ataluren) promoted readthrough of premature stop codons: a computational approach and GFP-reporter cell-based assay.
Lentini L; Melfi R; Di Leonardo A; Spinello A; Barone G; Pace A; Palumbo Piccionello A; Pibiri I
Mol Pharm; 2014 Mar; 11(3):653-64. PubMed ID: 24483936
[TBL] [Abstract][Full Text] [Related]
18. A double-blind, placebo controlled, dose ranging study to evaluate the safety and biological efficacy of the lipid-DNA complex GR213487B in the nasal epithelium of adult patients with cystic fibrosis.
Knowles MR; Noone PG; Hohneker K; Johnson LG; Boucher RC; Efthimiou J; Crawford C; Brown R; Schwartzbach C; Pearlman R
Hum Gene Ther; 1998 Jan; 9(2):249-69. PubMed ID: 9472784
[TBL] [Abstract][Full Text] [Related]
19. Discovery of Clinically Approved Agents That Promote Suppression of Cystic Fibrosis Transmembrane Conductance Regulator Nonsense Mutations.
Mutyam V; Du M; Xue X; Keeling KM; White EL; Bostwick JR; Rasmussen L; Liu B; Mazur M; Hong JS; Falk Libby E; Liang F; Shang H; Mense M; Suto MJ; Bedwell DM; Rowe SM
Am J Respir Crit Care Med; 2016 Nov; 194(9):1092-1103. PubMed ID: 27104944
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological treatment of the basic defect in cystic fibrosis.
Roomans GM
Cell Biol Int; 2014 Nov; 38(11):1244-6. PubMed ID: 24809326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
